Abiraterone in metastatic prostate cancer without previous chemotherapy.

Abstract

BACKGROUND Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We evaluated this agent in patients who had not received previous chemotherapy. METHODS In this double-blind study, we randomly assigned 1088 patients to receive abiraterone… (More)
DOI: 10.1056/NEJMoa1209096

Topics

  • Presentations referencing similar topics